Roche has obtained approval from the Japanese Ministry of Health, Labour and Welfare to market Avastin, or bevacizumab, as a treatment for malignant glioma, including newly diagnosed glioblastoma, in combination with radiotherapy and temozolomide, and as a monotherapy for recurrent GBM and certain kinds of high-grade glioma. The approval makes Avastin the first globally approved drug for newly diagnosed glioblastoma.

Related Summaries